Recurrent Ovarian Cancer Clinical Trial
— ProGem2Official title:
Phase 1B Open Label Study to Assess the Safety, Pharmacokinetics and Clinical Activity of Nuc-1031 Given on Days 1 & 8 With Carboplatin on Day 1, q3-weekly for 6 Cycles in Participants With Recurrent Ovarian Cancer.
Verified date | May 2021 |
Source | Imperial College Healthcare NHS Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A first in human experimental treatment in which an experimental medicine,Nuc-1031, is used in combination with a standard cancer medicine, carboplatin, to treat ovarian cancer which reappear after standard cancer treatment. The aim of the trial is to determine safety, effectiveness, and clinical activity of this combination treatment.
Status | Completed |
Enrollment | 25 |
Est. completion date | January 23, 2017 |
Est. primary completion date | January 23, 2017 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Provision of signed written informed consent. - Original diagnosis and/or histological confirmation of relapsed epithelial ovarian, fallopian tube or primary peritoneal cancer. - Relapse =24 months from completion of platinum (carboplatin or cisplatin) or platinum-containing regimen. - Age = 18 years. - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. - Measurable disease as defined by Response Evaluation Criteria In Solid Tumours (RECIST) criteria version 1.1; January 2009 and/or evaluable disease (evaluable: cytologically or radiologically detectable disease such as ascites, peritoneal deposits, or lesions which do not fulfill RECIST criteria version 1.1 for measurable disease) [1,2]. Participants for whom disease and response to therapy can be monitored by serum Cancer Antigen 125 (CA125) levels will also be eligible. - Adequate bone marrow function as defined by: White Blood Cells of = 3 x109/L, Absolute Neutrophil Count (ANC) of = 2.0 x 109/L, platelet count of = 100.0 x 109/L, and haemoglobin of = 9 g/dL. - Adequate liver function, as determined by: Serum total bilirubin =1.5 x Upper Limit of Normal [(ULN), Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) = 2.5 x ULN, albumin = 30g/L. - Adequate renal function assessed as glomerular filtration rate(GFR) = 60 mL/min using Cr51-ethylenediaminetetraacetic acid (EDTA) method. - Ability to comply with protocol requirements. - Participants must be postmenopausal (12 months of amenorrhea), surgically sterile or they must agree to use a physical method of contraception. Oral or injectable contraceptive agents cannot be the sole method of contraception. Participants of child-bearing potential must have a negative serum pregnancy test within seven days prior to the first study drug administration. Exclusion Criteria: - History of allergic reactions attributed to previous gemcitabine treatment. - Previous treatment with Nuc-1031. - History of allergic reactions attributed to previous carboplatin treatment. - Symptomatic Central Nervous System (CNS) or leptomeningeal metastases. - Prior chemotherapy, radiotherapy (other than short cycle of palliative radiotherapy for bone pain), or immunotherapy within 28 days of first receipt of study drug (within 6 weeks for nitrosoureas and mitomycin C). Hormone therapy within 14 days of first receipt of study drug. - Prior toxicities from chemotherapy or radiotherapy which have not regressed to Grade = 1 severity [National Cancer Institute -Common Terminology Criteria for Adverse Events, (NCI-CTCAE) version 4.03] except for neuropathy and alopecia. - Another active cancer (excluding basal cell carcinoma) within the last 3 years. - Participants with uncontrolled concomitant illness or active infection requiring IV antibiotics. - Participants with serious illnesses, medical conditions, or other medical history, including laboratory results, which, in the investigator's opinion, would be likely to interfere with a their participation in the study, or with the interpretation of the results. - Known Human Immunodeficiency Virus (HIV) or known active Hepatitis B or C. - Any condition (e.g., known or suspected poor compliance, psychological instability, geographical location, etc.) that, in the judgment of the investigator, may affect the participant's ability to sign the informed consent and undergo study procedures. - Currently pregnant, lactating or breastfeeding |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Garry Weston Cancer Centre, Hammersmith Hospital | London |
Lead Sponsor | Collaborator |
---|---|
Imperial College Healthcare NHS Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine the Recommended Phase II Dose (RP2D) of Nuc-1031 and carboplatin when administered in combination. | 1 year | ||
Secondary | To evaluate the safety and tolerability of Nuc-1031 administered in combination with carboplatin measured by adverse events (AE) and changes from baseline in vital signs, clinical laboratory parameters, and electrocardiography (ECG) assessments. | 1 year | ||
Secondary | To evaluate the objective response rate (ORR) of Nuc-1031 administered in combination with carboplatin in participants with recurrent ovarian cancer. | 1 year | ||
Secondary | To evaluate the clinical benefit rate (CBR) of Nuc-1031 administered in combination with carboplatin in participants with recurrent ovarian cancer. | 1 year | ||
Secondary | To evaluate the progression free survival (PFS) of participants with recurrent ovarian cancer treated with Nuc-1031 in combination with carboplatin. | 1 year | ||
Secondary | To evaluate Overall Best Response, utilising the evaluation criteria determined by the Gynecologic Cancer Intergroup (GCIG), combining the change in CA125 from baseline with RECIST 1.1 assessment | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02195973 -
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
|
Phase 1 | |
Not yet recruiting |
NCT05270720 -
Dendritic Cell Vaccination With Standard Postoperative Chemotherapy for the Treatment of Adult Ovarian Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06070285 -
Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients
|
||
Active, not recruiting |
NCT01802749 -
Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer
|
Phase 3 | |
Completed |
NCT02788708 -
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
|
Phase 1 | |
Recruiting |
NCT03564340 -
Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
|
Phase 1/Phase 2 | |
Recruiting |
NCT05610735 -
Combination Therapy for Recurrent Ovarian Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02083536 -
LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma
|
Phase 1 | |
Completed |
NCT03430518 -
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
|
Phase 1 | |
Recruiting |
NCT03618706 -
Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer
|
Phase 2 | |
Recruiting |
NCT05311579 -
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01851746 -
A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer
|
N/A | |
Active, not recruiting |
NCT06107868 -
Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer
|
Phase 1 | |
Recruiting |
NCT06308406 -
A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06365853 -
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
|
Phase 2 | |
Completed |
NCT04718740 -
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05335993 -
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
|
Phase 2 | |
Completed |
NCT01381861 -
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05126342 -
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
|
Phase 2 | |
Completed |
NCT02849353 -
Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer
|
Phase 1/Phase 2 |